Table 3 Factors associated with the occurrence of pneumocystis carinii pneumonia
Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
HR (95% CI) | P-value | HR (95% CI) | P-value | |
Rituximab treatment | 3.47 (1.84–6.56) | < 0.01 | 3.09 (1.60–5.96) | < 0.01 |
Rituximab dose = 0 mg | Reference | |||
≤ 200 mg | 1.84 (0.89–3.82) | 0.12 | – | – |
> 200 mg | 0.77 (0.18–3.23) | 0.72 | – | – |
Male vs. female | 1.40 (0.74–2.64) | 0.30 | – | – |
Acute rejection | 2.46 (1.23–4.92) | 0.01 | 2.19 (1.09–4.14) | 0.03 |
ABO-compatible and XM-negative | Reference | – | – | |
ABO-incompatible | 0.48 (0.07–3.56) | 0.47 | – | – |
XM-positive | 1.86 (0.89–3.89) | 0.10 | – | – |
ABO-incompatible and XM-positive | 1.18 (0.16–8.90) | 0.87 | – | – |
ABO incompatibe vs. compatible | 0.66 (0.16–2.75) | 0.56 | – | – |
XM positive vs. negative | 3.66 (0.33–40.37) | 0.29 | ||
ATG vs. basiliximab | 0.85 (0.20–3.57) | 0.85 | – | – |
CMV viremia prior to PCP | 1.94 (1.00–3.75) | 0.05 | 1.62 (0.82–3.20) | 0.16 |